

AMENDMENTS TO THE CLAIMS

This Listing of Claims will replace all prior versions, and listings, of claims in the application. With the amendments, claims 47-50, 55, 58, 69-71, 76, and 78-80 remain pending.

Listing of Claims:

1-46. (Canceled)

47. (Currently Amended) A method for treating a disease, disorder or condition of the respiratory system related to expression of a gene regulated by NF-KB, the method comprising the step of:

50-a) administering a composition in the form of a dry powder, the composition comprising a double-stranded oligonucleotide in a naked form and at least one excipient, which excipient is acceptable as a pharmaceutical additive for the dry powder, the composition being administered directly to the respiratory system of a subject suffering from the disease, disorder or condition, wherein said double-stranded oligonucleotide consists of an oligonucleotide having a sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 3 and an oligonucleotide complementary thereto and

~~The method according to claim 45, wherein said disease, disorder and/or condition of the respiratory system is COPD, asthma or rhinitis.~~

48. (Currently Amended) The method according to claim ~~47~~45, wherein said direct administration to the respiratory system comprises

administration into the airway, or the lung, or comprises transairway absorption or nasal absorption.

49. (Currently Amended) The method according to claim 4745, wherein said direct administration to the respiratory system is administration to the airway by atomization or inspiration.

50. (Currently Amended) The method according to claim 4745, wherein said direct administration to the respiratory system is achieved by means selected from the group consisting of a dry powder inhaler (DPI), a nasal drop, a spray, a nebulizer, a respirator and powder administration.

51-54. (Canceled)

55. (Currently Amended) The method according to claim 4745, wherein said oligonucleotide is an oligonucleotide containing one or more thiophosphatediester bonds or an oligonucleotide whose phosphatediester bond is substituted with a methylphosphate group.

56-57. (Canceled)

58. (Currently Amended) The method according to claim 4745, wherein said excipient is selected from the group consisting of lactose and light anhydrous silicic acid.

59-68. (Canceled)

69. (Currently Amended) The method according to claim ~~4745~~, wherein the dry powder has an aerodynamic average particle size of about 0.01 to about 50 micrometer.

70. (Previously Presented) The method according to claim 69, wherein the dry powder has an aerodynamic average particle size of about 0.05 to about 30 micrometer.

71. (Previously Presented) The method according to claim 70, wherein the dry powder has an aerodynamic average particle size of about 0.1 to about 10 micrometer.

72-75. (Canceled)

76. (Currently Amended) The method according to claim ~~4745~~, wherein a dosage of 10 mg to 100 mg per round of administration is provided.

77. (Canceled)

78. (Currently Amended) The method according to claim ~~4745~~, wherein the direct administration to the respiratory system comprises nasal absorption.

79. (Previously Presented) The method according to claim 78, wherein said nasal absorption is by means selected from the group consisting of a

nasal drop, a nasal spray agent, an agent for nebulizer, an agent for a respirator and a powder administration formulation.

80. (Previously Presented) The method according to claim 78, wherein said nasal absorption is by means a nasal drop and said disease of the respiratory system is rhinitis.

81-85. (Canceled)